Eli Lilly: Adjusted EPS up more than tenfold in Q3
(CercleFinance.com) - Eli Lilly reports Q3 global sales of $11.
44bn, up 20% on Q3 2023, supported by a 15% increase in volume and a 6% rise due to higher realized prices. NB: pmt -10.4%.
Adjusted net income came to $1,064m, up more than tenfold y-o-y($94.8m a year earlier), representing adjusted EPS of $1.18 vs. $0.10 a year earlier.
While the growth in sales of Mounjaro (from $1.4bn to $3.1bn) and Zepbound (which soared to $1.25bn) is impressive, we are also proud of the 17% growth in revenues, including the oncology, immunology and neuroscience portfolios, compared with the third quarter of 2023 on the same basis, the laboratory says in short.
Eli Lilly expects 2024 sales of $45.4bn and $46bn (compared with $45.4bn to $46.6bn previously).
Adjusted EPS is expected between $13.02 and $13.52 (vs. $16.1 and $16.6 previously).
Copyright (c) 2024 CercleFinance.com. All rights reserved.
44bn, up 20% on Q3 2023, supported by a 15% increase in volume and a 6% rise due to higher realized prices. NB: pmt -10.4%.
Adjusted net income came to $1,064m, up more than tenfold y-o-y($94.8m a year earlier), representing adjusted EPS of $1.18 vs. $0.10 a year earlier.
While the growth in sales of Mounjaro (from $1.4bn to $3.1bn) and Zepbound (which soared to $1.25bn) is impressive, we are also proud of the 17% growth in revenues, including the oncology, immunology and neuroscience portfolios, compared with the third quarter of 2023 on the same basis, the laboratory says in short.
Eli Lilly expects 2024 sales of $45.4bn and $46bn (compared with $45.4bn to $46.6bn previously).
Adjusted EPS is expected between $13.02 and $13.52 (vs. $16.1 and $16.6 previously).
Copyright (c) 2024 CercleFinance.com. All rights reserved.